Tango Therapeutics (TNGX)Farallon Capital Management, L.L.C. reduced its stake -3.96M shares

9.1M

Shares reported · -3.96M vs prior quarter

1.0%

Disclosed portfolio weight

$190M

Reported value

Holdings as of

Mar 31, 2026

Filed

Aug 14, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jun 19, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On June 19, 2026, the Board of Directors (the “Board”) of Tango Therapeutics, Inc. (the “Company”) increased the number of directors of the Company to seven (7).”
2. Jul 31, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“Dr. Barbara Weber’s employment with Tango Therapeutics, Inc. (the “Company”) as its Executive Chair ended on August 3, 2026 in accordance with the terms of her Amended and Restated Employment Agreement dated January 8, 2026 (the “Employment Agreement”).”
3. Jul 31, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On August 6, 2026, Dr. Weber and the Company executed the separation agreement (the “Separation Agreement”), which provides for Dr. Weber to receive: (i) severance pay at Dr. Weber’s current base salary through December 31, 2026, paid out in substantially equal installments, and (ii) reimbursement for any monthly COBRA premium payments up to December 31, 2026.”
4. Aug 11, 2026Company filing · Form 8-K · ResultsReported its results

What came next

1. Oct 1, 2026Insider · 1 personInsiders: 2 sales (~$661K)

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Tango Therapeutics

For Tango Therapeutics, OQRO holds 2 insider filings (SEC Form 4 or Form 144) and 11 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its TNGX page.

How this filing works

• SEC Form 13F

Other disclosures at Tango Therapeutics

• SEC Form 4Oct 6, 2026
• SEC Form 4Oct 6, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026

Everything OQRO holds on this company is on its TNGX page.